Anti-EGFR antibody is a Humanized antibody of IgG class that binds to an EGFR.
Figure 1 Binding of nimotuzumab, cetuximab and their monovalent fragments to human tumor cell lines with different EGFR expression.
(A) Immunoblot for the total EGFR and actin were performed for the indicated tumor cells.
Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.
Figure 2 Binding of nimotuzumab, cetuximab and their monovalent fragments to human tumor cell lines with different EGFR expression.
(B) Tumor cells (grey histograms) were stained with an anti-EGFR antibody (black histograms), followed by incubation with FITC-conjugated rabbit anti-rat IgG-H&L.
Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.
Figure 3 Examination of cetuximab and nimotuzumab binding kinetics using surface plasmon resonance.
(B) Under bivalent binding conditions (intended to represent binding to cells with high EGFR expression), antibodies behaved similarly and accumulated to the equivalent levels; ligand-FcEGFR chimera (dimer); analyte-100 nM anti-EGFR antibodies. Experiments were performed three times with similar results. Representative data are shown.
Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.
Figure 4 In vitro effects of nimotuzumab and cetuximab on cells with different EGFR expression levels.
(B) Cells treated with antibodies (70 nM) or their monovalent Fab fragments (140 nM) for 24 h were fixed with ice-cold methanol/acetone and stained with PI (400 μg/ml). The percentage of cells with DNA fragmentation (apoptotic cells) was analyzed by flow cytometry. For both experiments the U1906 cell line was used as a negative control for EGFR expression and the fenritenide was used as positive control in the apoptosis assay (data not shown). One representative experiment out of three is shown in each case.
Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.
Figure 5 Competition experiments performed for Nimotuzumab.
A, ELISA plates were coated with 5 μg/mL eEGFR and incubated with different mixtures containing a constant concentration of biotinylated Nimotuzumab Fab fragment and decreasing concentrations of the Cetuximab Fab fragment. OD, optical density.
Talavera, A., Friemann, R., Gómez-Puerta, S., Martinez-Fleites, C., Garrido, G., Rabasa, A., ... & Krengel, U. (2009). Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer research, 69(14), 5851-5859.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-056 | Recombinant Anti-Mouse Egfr VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
PNBL-016 | Recombinant Anti-Human EGFR VHH Single Domain Antibody (PNBL-016) | WB, ELISA | Llama VHH |
PNBL-017 | Recombinant Anti-Human EGFR VHH Single Domain Antibody (PNBL-017) | FuncS, ELISA, IF | Llama VHH |
PNBL-018 | Recombinant Anti-Human EGFR VHH Single Domain Antibody (PNBL-018) | FuncS, SPR | Llama VHH |
HPAB-AP881-YC | Recombinant Llama Anti-EGFR Single Domain Antibody (HPAB-AP881-YC) | ELISA, FC, IP, FuncS | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-165 | Anti-Human EGFR Recombinant Antibody (Matuzumab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | IgG1 |
TAB-710 | Anti-EGFR Recombinant Antibody (Nimotuzumab) | ELISA, IP, FC, FuncS, Neut, IF, IHC | IgG1 - kappa |
TAB-274MZ | Human Anti-EGFR Recombinant Antibody (TAB-274MZ) | FC | Humanized IgG |
TAB-297MZ | Anti-Human EGFR Recombinant Antibody (H225) | ELISA, WB | Humanized antibody |
TAB-274MZ-S(P) | Human Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-274MZ-S(P)) | FC | Humanized scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
PABW-088 | Mouse Anti-EGFR Recombinant Antibody (clone 7A7) | ELISA, WB | Mouse IgG |
HPAB-0727-CN | Mouse Anti-EGFR Recombinant Antibody (clone EGFR) | ELISA, FC, IHC, Neut | Mouse IgG1, κ |
HPAB-0161CQ | Human Anti-EGFR Recombinant Antibody (HPAB-0161CQ) | ELISA, FC, IHC | Human IgG1 |
HPAB-1443LY | Human Anti-EGFR Recombinant Antibody (clone P1X) | ELISA, WB | Human IgG |
HPAB-1444LY | Human Anti-EGFR Recombinant Antibody (clone P2X) | ELISA, WB | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-272MZ | Human Anti-EGFR Recombinant Antibody (TAB-272MZ) | FuncS | Chimeric (mouse/human) IgG |
TAB-302MZ | Human Anti-EGFR Recombinant Antibody (TAB-302MZ) | ELISA | Chimeric (mouse/human) IgG1 |
TAB-308MZ | Human Anti-EGFR Recombinant Antibody (TAB-308MZ) | FuncS | Chimeric antibody (mouse/human) |
TAB-272MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-272MZ-S(P)) | FuncS | Mouse scFv |
TAB-302MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-302MZ-S(P)) | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-299MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-299MZ-F(E)) | Internalization Assay | Human Fab |
TAB-313MZ-F(E) | Anti-Human EGFR Recombinant Antibody Fab Fragment (EG-19-11) | ELISA, FC | Human antibody |
TAB-314MZ-F(E) | Anti-Human EGFR Recombinant Antibody Fab Fragment (EG-26-11) | ELISA, FC | Human antibody |
PABX-052-S (P) | Recombinant Human Anti-EGFR Antibody scFv Fragment (Nimotuzumab) | WB, ELISA, FuncS | scFv |
PABX-053-S (P) | Recombinant Human Anti-EGFR Antibody scFv Fragment (DL11) | WB, ELISA, FuncS | scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-303MZ-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-303MZ-F(E)) | ELISA | Mouse Fab |
TAB-304MZ-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-304MZ-F(E)) | ELISA | Mouse Fab |
TAB-305MZ-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-305MZ-F(E)) | ELISA | Mouse Fab |
TAB-306MZ-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-306MZ-F(E)) | ELISA | Mouse Fab |
TAB-307MZ-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-307MZ-F(E)) | ELISA, FC | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-055LC | Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Chimeric antibody (mouse/human) |
Gly-144LC | Recombinant Anti-Human EGFR Antibody (Fc glycosylation) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-055LC-1 | Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-167LC | Recombinant Anti-Human EGFR Antibody (Non-glycosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0183MZ | Chicken Anti-EGFR Polyclonal IgY | WB | Chicken antibody |
BRD-0668MZ | Chicken Anti-EGFR Polyclonal IgY | WB | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-LC773 | A*0201/Human EGFR (YLNTVQPTCV) MHC Tetramer | FCM | |
MHC-LC4545 | PE-DQB1*03:02/Human EGFR (SRALEEKKGNYVVTHG) MHC Tetramer | FCM | |
MHC-YF409 | A*02:01/Human EGF-R-479 (KLFGTSGQKT) MHC Pentamer | FCM |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-722CQ | Rabbit Anti-EGFR Recombinant Antibody (clone CBL1011) | Neut | Rabbit IgG |
NEUT-723CQ | Mouse Anti-EGFR Recombinant Antibody (clone CBL931) | WB, IP, IHC, ICC, Neut | Mouse IgG1 |
NEUT-724CQ | Rabbit Anti-EGFR Recombinant Antibody (clone D1D4J) | IF, FC, WB, IP, Neut | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1101 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone DS1101AB) | IHC-P | Rabbit IgG |
MOR-4520 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH28DS) | IF, ICC, FC | Rabbit IgG |
MOR-4570 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH82DS) | ELISA | Rabbit IgG |
MOR-4675 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH189DS) | WB, IF, ICC, FC | Rabbit IgG |
MOR-4676 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH190DS) | WB, IF, ICC, FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0010-YC-F(E) | Mouse Anti-EGFR Recombinant Antibody (clone L211C); Fab Fragment | ELISA, FC | Mouse Fab |
HPAB-0011-YC-F(E) | Human Anti-EGFR Recombinant Antibody (clone Pep 1); Fab Fragment | FC | Human Fab |
HPAB-0012-YC-F(E) | Human Anti-EGFR Recombinant Antibody (clone Pep 2); Fab Fragment | FC | Human Fab |
HPAB-0013-YC-F(E) | Human Anti-EGFR Recombinant Antibody (clone Pep 3); Fab Fragment | FC | Human Fab |
HPAB-0014-YC-F(E) | Human Anti-EGFR Recombinant Antibody (clone Pep 4); Fab Fragment | FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-165 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-464CQ | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
AFC-TAB-003 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-040 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-020 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Panitumumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-S0019-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E2.11); scFv Fragment | ELISA, Inhib | Human scFv |
HPAB-S0020-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E6.2); scFv Fragment | ELISA, Inhib | Human scFv |
HPAB-S0021-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E6.3); scFv Fragment | ELISA, Inhib | Human scFv |
HPAB-S0022-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E7.6.3); scFv Fragment | ELISA, Inhib, FuncS | Human scFv |
HPAB-S0023-YC-S(P) | Mouse Anti-EGFR Recombinant Antibody (clone 14E1); scFv Fragment | IB, FuncS | Mouse scFv |
There are currently no Customer reviews or questions for PABX-052. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.